Tandem Competitors

Stocks . USA . 
Stock . Tandem Diabetes Care
TNDM Stock  USD 19.76  0.65  3.40%   
Tandem Diabetes Care competes with Integra LifeSciences, Kodiak Sciences, Nurix Therapeutics, InMode, and UroGen Pharma; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Tandem Diabetes competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Tandem Diabetes to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Tandem Diabetes Correlation with its peers.

Tandem Diabetes vs Fortrea Holdings Correlation

Poor diversification

The correlation between Tandem Diabetes Care and FTRE is 0.73 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Tandem Diabetes Care and FTRE in the same portfolio, assuming nothing else is changed.

Moving against Tandem Stock

  0.75NIO Nio Class APairCorr
  0.54NVDA NVIDIA Aggressive PushPairCorr
  0.53GRAB Grab HoldingsPairCorr
  0.52PLUG Plug PowerPairCorr
  0.46PG Procter GamblePairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Tandem Diabetes' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
15.3719.7624.15
Details
Intrinsic
Valuation
LowRealHigh
14.7119.1023.49
Details
Naive
Forecast
LowNextHigh
14.8119.2123.60
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
19.0121.3423.66
Details

Tandem Diabetes Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Tandem Diabetes and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Tandem and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Tandem Diabetes Care does not affect the price movement of the other competitor.

High positive correlations

FTRE
+ 0.92
KOD
NRIX
+ 0.89
KOD
EYPT
+ 0.89
NRIX
EYPT
+ 0.88
KOD
SEPN
+ 0.85
NRIX
FTRE
+ 0.85
NRIX
  

High negative correlations

FTRE
- 0.38
URGN
URGN
- 0.27
KOD
TNGX
- 0.26
URGN
URGN
- 0.18
INMD
URGN
- 0.14
NRIX
TNGX
- 0.11
PHAT

Risk-Adjusted Indicators

There is a big difference between Tandem Stock performing well and Tandem Diabetes Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Tandem Diabetes' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
IART  2.17 (0.21) 0.00 (0.05) 0.00 
 0.00 
 5.40 
(3.55)
 15.12 
KOD  3.82  0.59  0.15  0.54  3.48 
(4.23)
 8.06 
(6.81)
 21.00 
NRIX  3.11  0.58  0.15  2.81  3.01 
(3.73)
 7.07 
(5.05)
 27.63 
INMD  1.38  0.10  0.05  0.15  1.85 
(1.55)
 2.37 
(2.12)
 11.78 
URGN  3.33  0.12  0.02 (80.71) 4.07 
(4.04)
 6.25 
(5.50)
 36.24 
EYPT  3.12  0.30  0.06 (0.77) 3.59 
(3.45)
 6.24 
(4.89)
 22.25 
SEPN  3.39  0.32  0.08  1.41  3.16 
(4.01)
 7.41 
(5.00)
 27.98 
PHAT  2.87  0.05  0.00  0.55  3.80 
(2.99)
 5.99 
(4.86)
 24.16 
TNGX  3.89  0.75  0.17 (3.36) 3.59 
(4.81)
 11.29 
(6.19)
 31.20 
FTRE  3.58  0.75  0.24  0.28  3.14 
(4.65)
 8.57 
(5.60)
 33.07 

Tandem Diabetes Competitive Analysis

The better you understand Tandem Diabetes competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Tandem Diabetes' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Tandem Diabetes' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TNDM IART KOD NRIX INMD URGN EYPT SEPN PHAT TNGX
 3.40 
 19.76 
Tandem
 1.93 
 11.09 
Integra
 2.45 
 25.43 
Kodiak
 1.57 
 17.59 
Nurix
 5.95 
 16.02 
InMode
 2.95 
 20.69 
UroGen
 1.93 
 14.75 
Eyepoint
 0.59 
 23.80 
Septerna
 2.24 
 13.53 
Phathom
 4.38 
 11.67 
Tango
Market Volatility
(90 Days Market Risk)
Not too volatile
Not too volatile
Not too volatile
Somewhat reliable
Not too volatile
Somewhat reliable
Somewhat reliable
Not too volatile
Somewhat reliable
Slightly risky
Market Performance
(90 Days Performance)
Good
Weakest
Good
Fair
Mild
Weak
Mild
Mild
Weak
Fair
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Small
Low
Low
Low
High
Low
Low
Risky
Low
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Under Valued
Fairly Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Hold
Hold
Hold
Cautious Hold
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
4.8
3.85
8.65
5.26
9.74
7.74
6.16
N/A
9.93
9.76
Net Asset
967.66 M
4.04 B
335.58 M
669.34 M
785.67 M
285.71 M
418.46 M
456.55 M
378.32 M
316.49 M
Profit Margin
-0.2
-0.3
N/A
-2.92
0.41
-1.71
N/A
-2.67
-1.87
-1.51
EBITDA
(99.13 M)
193.29 M
(149.5 M)
(205.01 M)
113.26 M
(95.35 M)
(129.23 M)
(79.42 M)
(261.52 M)
(143.1 M)
Operating Margin
-0.0805
0.0992
N/A
-11.58
0.22
-1.0
-64.21
-0.46
-0.31
0.26
Current Valuation
1.5 B
2.6 B
1.49 B
1.53 B
429.01 M
988.05 M
1.13 B
689.27 M
1.17 B
1.48 B
Price To Book
10.28
0.84
63.21
5.11
1.46
19.27
6.54
2.93
25.37
9.97
Retained Earnings
(1.05 B)
939.91 M
(1.33 B)
(738.77 M)
874.7 M
(806.22 M)
(873.02 M)
(118.37 M)
(1.26 B)
(501.56 M)
Current Asset
106.98 M
438.5 M
7.31 M
N/A
75.11 M
N/A
15.08 M
N/A
N/A
N/A
Beta
1.69
1.03
2.67
1.94
2.13
1.3
1.65
N/A
0.49
1.75
Number Of Employees
2.65 K
4.4 K
123
286
599
287
165
75
427
155
Shares Outstanding
67.8 M
77.89 M
61.05 M
101.37 M
63.21 M
46.81 M
82.79 M
44.77 M
78.01 M
134.68 M
Cash Flow From Operations
24.23 M
129.38 M
(117.32 M)
(172.58 M)
132.66 M
(96.77 M)
(126.23 M)
(67.47 M)
(266.77 M)
(131.5 M)
Total Debt
473.56 M
1.98 B
70.34 M
28.3 M
7.82 M
123.39 M
21.86 M
25.48 M
554.95 M
36.49 M
Return On Equity
-1.1
-0.39
-2.08
-0.65
0.22
-14.81
-0.98
-0.22
-34.89
-0.52
Return On Asset
-0.0594
0.0261
-0.47
-0.32
0.07
-0.34
-0.49
-0.14
-0.43
-0.25
Number Of Shares Shorted
9 M
7.43 M
7.13 M
15.2 M
3.19 M
10.57 M
8.27 M
1.94 M
10.52 M
42.75 M
Book Value Per Share
1.96
13.33
0.45
4.84
10.32
-2.47
2.88
8.71
-5.95
1.43
Current Liabilities
26.52 M
139.13 M
4.89 M
N/A
55.5 M
N/A
11.26 M
N/A
N/A
N/A
Total Asset
967.66 M
4.04 B
335.58 M
669.34 M
785.67 M
285.71 M
418.46 M
456.55 M
378.32 M
316.49 M
Debt To Equity
1.0
1.03
0.16
0.038
0.007
0.44
0.3
N/A
2.43
0.002
Short Ratio
6.75
10.57
6.18
7.68
4.9
11.5
7.22
5.28
11.7
15.73
Target Price
25.95
15.5
29.0
29.59
16.6
35.25
36.08
33.86
22.9
13.63
Shares Owned By Institutions
99.01
96.39
77.7
83.52
60.0
98.45
88.4
96.85
80.85
97.47
Market Capitalization
1.3 B
847.67 M
1.5 B
1.97 B
1.03 B
1.02 B
1.25 B
1.14 B
1.11 B
1.6 B
Price To Earning
494.25
26.94
-2.29
N/A
20.78
239.57
-2.82
N/A
N/A
N/A
Price To Earnings To Growth
N/A
0.71
-0.08
N/A
2.9
N/A
N/A
N/A
N/A
N/A
Price To Sales
1.29
0.52
N/A
23.51
2.82
10.6
29.41
51.69
7.54
24.0
Net Income
(96.03 M)
(6.94 M)
(176.21 M)
(193.57 M)
181.28 M
(126.87 M)
(130.87 M)
(71.8 M)
(334.33 M)
(130.3 M)
Earnings Per Share
-3.03
-6.47
-4.12
-2.97
2.08
-3.47
-3.0
-6.9
-3.76
-0.91
Shares Owned By Insiders
0.99
13.95
4.77
1.09
10.64
3.85
2.76
3.15
4.69
4.95
Revenue
940.2 M
1.61 B
N/A
54.55 M
394.82 M
90.4 M
43.27 M
1.07 M
55.25 M
42.07 M
Working Capital
477.44 M
159.56 M
146.36 M
523.53 M
644.6 M
230.19 M
334.26 M
343.98 M
274.41 M
228.17 M
Cash And Equivalents
608.73 M
451.52 M
597.88 M
344.48 M
486.39 M
111.74 M
171.17 M
N/A
207.39 M
416.36 M
Cash Per Share
9.47
5.41
11.55
7.31
5.91
4.91
5.02
N/A
5.39
4.73
Gross Profit
536.01 M
944.73 M
N/A
(217.42 M)
287.31 M
84.89 M
(161.42 M)
22.05 M
128.42 M
(67.5 M)
Day Typical Price
19.51
10.99
25.6
18.04
15.93
20.85
14.9
24.09
13.73
11.46
Accumulation Distribution
98565.37
24224.01
28141.12
172502.0
69535.44
26773.78
29394.05
13166.1
21480.93
83561.65
Daily Balance Of Power
0.6771
0.5385
(0.39)
(0.13)
2.25
(0.45)
(0.43)
0.1228
(0.48)
0.6806
Period Momentum Indicator
0.65
0.21
(0.64)
(0.28)
0.9
(0.63)
(0.29)
0.14
(0.31)
0.49
Rate Of Daily Change
1.03
1.02
0.98
0.98
1.06
0.97
0.98
1.01
0.98
1.04
Day Median Price
19.38
10.95
25.69
18.27
15.89
20.94
14.98
24.24
13.83
11.36
Price Action Indicator
0.71
0.25
(0.58)
(0.82)
0.58
(0.56)
(0.37)
(0.37)
(0.46)
0.55
Relative Strength Index
50.22
40.4
51.3
50.22
61.61
48.44
45.46
46.25
44.58
57.28
Coefficient Of Variation
669.1
(3,277)
709.9
750.62
1438.55
3711.52
1519.77
1379.31
5442.24
757.38
Mean Deviation
2.99
2.17
3.82
3.11
1.38
3.33
3.12
3.39
2.87
3.89
Jensen Alpha
0.5828
(0.21)
0.5912
0.5802
0.0988
0.1211
0.2969
0.3181
0.0547
0.7492
Total Risk Alpha
0.3361
(0.31)
0.3204
0.2722
(0.01)
(0.22)
(0.03)
(0)
(0.21)
0.3376
Sortino Ratio
0.1879
N/A
0.1524
0.1532
0.0482
0.0166
0.0595
0.0828
0.0023
0.1666
Downside Variance
10.03
N/A
15.59
12.42
4.07
17.73
14.58
11.35
14.98
16.99
Standard Deviation
4.39
2.92
4.71
4.51
2.28
4.86
4.38
4.69
3.83
5.66
Kurtosis
8.39
1.05
(0.1)
4.04
10.4
6.53
2.5
5.2
2.28
3.6
Potential Upside
7.03
5.4
8.06
7.07
2.37
6.25
6.24
7.41
5.99
11.29
Treynor Ratio
0.5206
(0.05)
0.5417
2.81
0.1531
(80.71)
(0.77)
1.41
0.549
(3.36)
Maximum Drawdown
27.14
15.12
21.0
27.63
11.78
36.24
22.25
27.98
24.16
31.2
Variance
19.3
8.53
22.16
20.35
5.21
23.66
19.21
22.0
14.68
32.09
Market Risk Adjusted Performance
0.5306
(0.04)
0.5517
2.82
0.1631
(80.70)
(0.76)
1.42
0.559
(3.35)
Risk Adjusted Performance
0.1169
(0.01)
0.1107
0.1051
0.0573
0.0281
0.0561
0.0611
0.0214
0.1046
Skewness
1.9
0.8331
0.5182
1.26
0.8457
1.02
0.8056
1.69
(0.25)
1.46
Semi Deviation
2.95
N/A
3.48
3.01
1.85
4.07
3.59
3.16
3.8
3.59
Information Ratio
0.1355
(0.05)
0.1278
0.1196
0.0426
0.0143
0.0518
0.0594
0.0024
0.1212
Value At Risk
(4.34)
(3.55)
(6.81)
(5.05)
(2.12)
(5.50)
(4.89)
(5.00)
(4.86)
(6.19)
Expected Short fall
(3.58)
N/A
(4.23)
(3.73)
(1.55)
(4.04)
(3.45)
(4.01)
(2.99)
(4.81)
Downside Deviation
3.17
N/A
3.95
3.52
2.02
4.21
3.82
3.37
3.87
4.12
Semi Variance
8.69
N/A
12.08
9.07
3.42
16.55
12.92
10.0
14.41
12.86

Tandem Diabetes Competition Performance Charts

Five steps to successful analysis of Tandem Diabetes Competition

Tandem Diabetes' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Tandem Diabetes Care in relation to its competition. Tandem Diabetes' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Tandem Diabetes in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Tandem Diabetes' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Tandem Diabetes Care, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Tandem Diabetes position

In addition to having Tandem Diabetes in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corporate Bonds Funds Thematic Idea Now

Corporate Bonds Funds
Corporate Bonds Funds Theme
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Tandem Diabetes Care is a strong investment it is important to analyze Tandem Diabetes' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tandem Diabetes' future performance. For an informed investment choice regarding Tandem Stock, refer to the following important reports:
How To Invest In Tandem
Details
Is Tandem Stock a good investment?
Details
What is Tandem Diabetes' Net Worth?
Details
Top Sectors
View
Check out Tandem Diabetes Correlation with its peers.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Stock sector continue expanding? Could Tandem diversify its offerings? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Tandem Diabetes data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Tandem Diabetes Care requires distinguishing between market price and book value, where the latter reflects Tandem's accounting equity. The concept of intrinsic value—what Tandem Diabetes' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Tandem Diabetes' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tandem Diabetes' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY